CCDC100 Inhibitors
Chemical inhibitors of CCDC100 operate through diverse mechanisms to modulate its activity. Staurosporine is a broad-spectrum kinase inhibitor that can suppress the phosphorylation of various proteins, including CCDC100, by targeting protein kinase C (PKC). This action results in a reduced ability of CCDC100 to engage in its normal cellular functions, which often depend on its phosphorylation state. Similarly, Bisindolylmaleimide I specifically inhibits PKC, which could be responsible for phosphorylating CCDC100, and thus, its inhibition can lead to decreased CCDC100 activity. Emodin functions as a tyrosine kinase inhibitor, which can indirectly affect the phosphorylation and subsequent activity of CCDC100, as tyrosine kinases may phosphorylate CCDC100 and regulate its function.
In the MAPK pathway, PD 98059 and U0126 serve as inhibitors of MEK, which is an upstream kinase that activates the ERK pathway, a common route for the regulation of protein function through phosphorylation. The inhibition of this pathway by PD 98059 or U0126 can result in reduced phosphorylation and activity of CCDC100 if it is a downstream target. Additionally, SB203580 and SP600125 target different components of the MAPK pathway, namely p38 MAPK and JNK, respectively. The inhibition of these kinases can lead to a decrease in CCDC100 activity if it is regulated by these pathways. On another front, LY294002 and Wortmannin inhibit PI3K, and Rapamycin targets mTOR, both of which are part of the PI3K/AKT/mTOR signaling pathway. Inhibition of these pathways can disrupt the phosphorylation status and activity of CCDC100 if it is involved in these signaling cascades. Lastly, PP2 and Dasatinib inhibit Src family tyrosine kinases and c-KIT, which can phosphorylate a variety of proteins. If CCDC100 is a substrate for these kinases, its activity can be reduced upon their inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C (PKC), which is involved in a myriad of cellular processes. Inhibition of PKC can lead to reduced phosphorylation of downstream targets, which may include CCDC100, thereby hindering its protein-protein interactions and functions. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $105.00 $214.00 $6255.00 | 2 | |
Emodin is a tyrosine kinase inhibitor that can indirectly inhibit CCDC100 by affecting kinases which are likely to phosphorylate CCDC100, thus preventing its proper functioning in cellular mechanisms where phosphorylation is a regulatory event. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I specifically inhibits PKC, which could be responsible for the phosphorylation state of CCDC100, thus the inhibition of PKC would result in a decrease in CCDC100 activity due to lack of phosphorylation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which is upstream of the MAPK/ERK pathway. Inhibition of this pathway can reduce the phosphorylation of various proteins, potentially including CCDC100, thereby inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, it can alter the AKT signaling pathway. Since AKT can phosphorylate a multitude of proteins, the inhibition of PI3K could indirectly lead to a reduction in CCDC100 activity if CCDC100 is a substrate of AKT or a downstream effector. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 works as an inhibitor of MEK1/2, which in turn are critical for the activation of ERK1/2 in the MAPK pathway. By inhibiting this pathway, CCDC100 function can be indirectly inhibited if it relies on the MAPK pathway for its activation or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, and if CCDC100 function is influenced by p38 MAPK signaling, its inhibition could result in diminished CCDC100 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another inhibitor of PI3K. By inhibiting PI3K, this chemical can impair the PI3K/AKT pathway, which could lead to a decrease in CCDC100 activity if CCDC100 is part of this signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. Inhibition of JNK can lead to reduced activity of proteins regulated by this pathway, possibly including CCDC100 if it is a JNK substrate. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a central protein in the PI3K/AKT/mTOR pathway. If CCDC100 is regulated by or interacts with components of this pathway, the inhibition of mTOR could result in diminished CCDC100 activity. | ||||||